PE-22-28

Quickstart Highlights

PE-22-28 is a synthetic heptapeptide (sequence: GVSWGLR) derived from the sortilin propeptide, engineered as a potent and selective antagonist of TREK-1 potassium channels. Preclinical studies demonstrate rapid antidepressant-like effects, enhanced neurogenesis, and neuroprotection with a favorable safety profile showing no cardiac or metabolic side effects. This educational protocol presents a once-daily subcutaneous approach with gradual titration.

• Reconstitute: Add 1.0 mL BAC water per labelled 10 mg vial; calculations assume a final volume of 1.0 mL and nominal concentration of 10 mg/mL.
• Typical daily range: 50–100 mcg once daily (conservative titration) for a 4–8 week cycle.
• Scale conversion: At 10 mg/mL, 1 U-100 unit = 0.01 mL = 100 mcg. Confirm actual device markings; this arithmetic does not establish measurement accuracy.
• Storage: Lyophilized: freeze at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F); protect from light.

Protocol Overview

Concise summary of the once-daily regimen.

• Goal: Support rapid neuroplasticity, mood regulation, and neuroprotection through selective TREK-1 inhibition.
• Schedule: Daily subcutaneous injections for 4–8 weeks, followed by 2–4 weeks off.
• Dose Range: 50–100 mcg daily with conservative titration; many find 100 mcg adequate.
• Reconstitution: 1.0 mL BAC per labelled 10 mg vial; nominal 10 mg/mL under the stated final-volume assumption.
• Storage: Lyophilized frozen; reconstituted refrigerated; replace vials every 4 weeks.

Dosing Protocol

Suggested conservative daily titration approach.

• Start: 50 mcg daily for Weeks 1–2 to assess tolerance.
• Increase: 100 mcg daily for Weeks 3–8 (standard maintenance dose).
• Frequency: Once per day (subcutaneous).
• Cycle Length: 4–8 weeks; then 2–4 weeks off. No extension; there is no human data to support longer continuous use.
• Timing: Consistent daily time; rotate injection sites systematically.

Storage Instructions

Proper storage preserves peptide quality and potency.

• Lyophilized: Store at −20 °C (−4 °F) in dry, dark conditions; minimize moisture exposure.
• Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); use within 4 weeks for optimal potency.
• Allow vials to reach room temperature before opening to reduce condensation; protect from light.
• Replace with fresh vial every 4 weeks even if peptide remains; bacteriostatic water sterility is guaranteed for 28 days after first puncture.

Important Notes

Practical considerations for consistency and safety.

• Use new sterile insulin syringes for each injection; dispose in a sharps container immediately.
• Rotate injection sites (abdomen, thighs, upper arms) systematically to reduce local irritation.
• Inject slowly; wait a few seconds before withdrawing the needle to prevent leakage.
• Document daily dose, site rotation, and any observations to maintain protocol consistency.
• Given PE-22-28’s high potency (IC₅₀ ~0.12 nM), conservative dosing is recommended; most preclinical effects occurred at low microgram ranges.

How This Works

PE-22-28 functions as a potent and selective antagonist of TREK-1 (KCNK2) two-pore domain potassium channels. By blocking TREK-1, it depolarizes neurons and enhances excitability, leading to increased firing of serotonergic neurons and elevated monoamine neurotransmission. This mechanism produces rapid antidepressant-like effects in preclinical models—within 4 days, PE-22-28 significantly increases hippocampal neurogenesis and synaptogenesis markers, changes typically requiring weeks with conventional antidepressants. The peptide also activates CaMKII/CREB pathways that promote neuronal survival and plasticity. PE-22-28 represents a shortened, optimized analog of spadin with superior potency (IC₅₀ ~0.12 nM versus 40–60 nM for spadin) and longer duration of action (~23 hours versus ~7 hours). Notably, research also demonstrates neuroprotective effects in stroke models through biphasic dosing that leverages both TREK-1 activation at ultra-low doses and inhibition at standard doses.

Potential Benefits & Side Effects

Observations from preclinical literature and mechanistic studies.

• Rapid Antidepressant Effects: Produces behavioral improvements within 4 days in rodent models; reduces immobility in forced swim tests and decreases latency to feed in novel environments.
• Enhanced Neuroplasticity: Increases hippocampal neurogenesis, synaptogenesis markers (PSD-95), dendritic spine density, and BDNF expression within days.
• Neuroprotection: In stroke models, preserves dopaminergic neurons, reduces motor deficits, and prevents post-stroke depressive behavior.
• Favorable Safety Profile: Shows high selectivity with no effects on hERG channels (cardiac safety), no impact on heart rate, blood pressure, glucose regulation, or pain perception in preclinical studies. No TREK-1-related side effects or withdrawal observed.
• No Human Data: All evidence is from cell culture and animal studies; human safety and pharmacokinetics remain unestablished.
• Potential Mild Reactions: Subcutaneous administration may occasionally cause minor injection-site reactions (slight redness or tenderness).

Lifestyle Factors

• Complementary strategies to support neuroplasticity and mood optimization.
  • Maintain consistent sleep schedule and prioritize 7–9 hours of quality sleep to support neurogenesis.
  • Engage in regular physical activity; both aerobic exercise and resistance training enhance BDNF and mood-regulating pathways.
  • Follow a nutrient-dense diet rich in omega-3 fatty acids, antioxidants, and B-vitamins to support brain health.
  • Practice stress-management techniques (meditation, mindfulness, therapy) to complement neuroplastic adaptations.
  • Consider cognitive training or novel learning activities to synergize with enhanced synaptic plasticity.

Injection Technique

General subcutaneous guidance from clinical best-practice resources.

• Clean the vial stopper and injection site with alcohol; allow both to air-dry completely.
• Pinch a skinfold of subcutaneous tissue; insert the needle at 45° (or 90° if using very short needles with ample subcutaneous fat).
• Do not aspirate for subcutaneous injections; inject solution slowly and steadily.
• Rotate sites systematically (abdomen at least 2 inches from navel, front/outer thighs, outer upper arms) to prevent lipohypertrophy and maintain absorption consistency.
• Given the very small injection volumes (often ≤0.10 mL), technique precision is critical. Consider using 30- or 50-unit insulin syringes for doses under 10 units to improve measurement accuracy.
• Withdraw needle at the same angle inserted; apply gentle pressure if needed; dispose of syringe immediately in sharps container.

Recommended Source

Note: Product availability and specifications subject to change. Verify current product details on supplier website.
Browse Amino Labs